New stock news | Anhui Huaheng Biotechnology Co., Ltd. (688639.SH) Hong Kong IPO prospectus invalid.

Anhui Huaheng Biotechnology Co., Ltd. (referred to as Anhui Huaheng Biotechnology Co., Ltd., 688639.SH) submitted its Hong Kong stock prospectus on September 30, 2025, which expired after 6 months on March 30, 2026, with Huatai International as the exclusive sponsor at the time of submission. According to the prospectus, as a global pioneer in synthetic biology technology, Anhui Huaheng Biotechnology Co., Ltd. focuses on research and development, large-scale production, and commercialization of bio-based products using biomanufacturing technology. The company has advanced research and development capabilities, strong technological innovation, and mature mass production capabilities, aiming to transform laboratory technology achievements into green, low-carbon, and high-performance bio-based products and solutions to meet emerging application scenarios. With twenty years of deep cultivation in the field of biomanufacturing, the company has established a leading position in research and development, technology, and the market. According to Frost & Sullivan data: the company is one of the most comprehensive bio-based product enterprises globally to achieve commercial application products through synthetic biology technology; the company is the first globally to achieve industrialization of series amino acids (including L-proline and L-leucine) through anaerobic fermentation; and based on revenue in 2024, the company ranks first globally in market share for L-proline and L-leucine.